ExodusPoint Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

ExodusPoint Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$58.4K	Sell	37,430 -231,003	-86%	-$336K	﹤0.01%	1457
2025 Q4	$309K	Buy	+268,433	New	+$369K	﹤0.01%	1306
2025 Q3	–	Sell	-12,241	Closed	-$12K	–	1819
2025 Q2	$12K	Buy	+12,241	New	+$7.93K	﹤0.01%	1393
2024 Q2	–	Sell	-319,058	Closed	-$766K	–	1784
2024 Q1	$766K	Buy	+319,058	New	+$685K	0.01%	1030
2023 Q2	–	Sell	-15,536	Closed	-$38K	–	2085
2023 Q1	$38K	Buy	+15,536	New	+$35.6K	﹤0.01%	1672
2022 Q2	–	Sell	-16,301	Closed	-$34K	–	2226
2022 Q1	$34K	Sell	16,301 -17,600	-52%	-$48.8K	﹤0.01%	2088
2021 Q4	$134K	Buy	33,901 +9,700	+40%	+$47.1K	﹤0.01%	1904
2021 Q3	$116K	Sell	24,201 -7,637	-24%	-$31.3K	﹤0.01%	1884
2021 Q2	$146K	Sell	31,838 -53,777	-63%	-$259K	﹤0.01%	2065
2021 Q1	$503K	Buy	+85,615	New	+$593K	0.01%	1342
2020 Q3	–	Sell	-25,622	Closed	-$51K	–	2029
2020 Q2	$51K	Buy	+25,622	New	+$50.2K	﹤0.01%	1681
2019 Q4	–	Sell	-136,840	Closed	-$412K	–	1728
2019 Q3	$412K	Buy	+136,840	New	+$424K	0.01%	742

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

ExodusPoint Capital Management's LXRX Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Lexicon Pharmaceuticals (LXRX) stake by 86% in Q1 2026, selling an estimated $336K and leaving 37,430 shares worth $58.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1457.

ExodusPoint Capital Management first reported a position in LXRX in Q3 2019 and has held it in 12 quarters since. The position peaked at $766K in Q1 2024. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

ExodusPoint Capital Management held 37,430 shares of Lexicon Pharmaceuticals worth $58.4K as of Q1 2026.
ExodusPoint Capital Management sold 231,003 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $336K.
Lexicon Pharmaceuticals made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1457 holding.
ExodusPoint Capital Management first reported a position in Lexicon Pharmaceuticals in Q3 2019 and has held it in 12 quarters since.
ExodusPoint Capital Management's Lexicon Pharmaceuticals position peaked at $766K in Q1 2024.
136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.